MiMedx Group Inc MDXG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"
-
THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'
-
MIMEDX to Participate in Upcoming Investor Conferences
-
DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT
-
MIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
-
MIMEDX Announces Second Quarter 2024 Operating and Financial Results
-
MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
-
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
Trading Information
- Previous Close Price
- $5.65
- Day Range
- $5.70–5.87
- 52-Week Range
- $5.57–9.27
- Bid/Ask
- $5.82 / $5.83
- Market Cap
- $855.90 Mil
- Volume/Avg
- 391,591 / 696,574
Key Statistics
- Price/Earnings (Normalized)
- 23.28
- Price/Sales
- 2.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.29%
Company Profile
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 895
- Website
- https://www.mimedx.com
Comparables
Valuation
|
Metric
|
MDXG
|
AORT
|
SIBN
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.28 | 103.15 | — |
Price/Book Value | 5.09 | 3.80 | 3.37 |
Price/Sales | 2.79 | 2.97 | 3.62 |
Price/Cash Flow | 11.70 | 23.40 | — |
Price/Earnings
MDXG
AORT
SIBN
Financial Strength
|
Metric
|
MDXG
|
AORT
|
SIBN
|
|---|---|---|---|
Quick Ratio | 3.04 | 2.65 | 7.99 |
Current Ratio | 3.85 | 5.63 | 9.17 |
Interest Coverage | 14.92 | 0.96 | −12.97 |
Quick Ratio
MDXG
AORT
SIBN
Profitability
|
Metric
|
MDXG
|
AORT
|
SIBN
|
|---|---|---|---|
Return on Assets (Normalized) | 18.96% | 1.39% | −6.03% |
Return on Equity (Normalized) | 44.00% | 3.82% | −8.10% |
Return on Invested Capital (Normalized) | 34.36% | 5.06% | −8.97% |
Return on Assets
MDXG
AORT
SIBN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jwnmpcxxgz | Tnp | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yhpckjnxm | Chdpn | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wglpjvjyd | Wmmdtw | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Svxpgnmfp | Cqjndx | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Psxllpll | Bvwv | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ybrzdybz | Yvvf | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ymwtcrq | Vkfl | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Ynvslcnhj | Bmrkd | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zxhrcbyn | Kbydg | $13.4 Bil | |||
| Incyte Corp
INCY
| Gkrvpjmhj | Gqfhxq | $12.7 Bil |
United States